ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Allopurinol"

  • Abstract Number: 1106 • 2017 ACR/ARHP Annual Meeting

    Association between ABCG2 rs2231142 and Poor Response to Allopurinol: Replication and Meta-Analysis

    Mary Wallace1, Rebecca Roberts2, Payal Nanavati3, Jeffrey N Miner3, Nicola Dalbeth4, Ruth Topless5, Tony R. Merriman6 and Lisa K. Stamp7, 1Surgical Sciences, University of Otago, Dunedin, New Zealand, 2University of Otago, Dunedin, New Zealand, 3Ardea Biosciences, San Diego, CA, 4University of Auckland, Auckland, New Zealand, 5Department of Biochemistry, University of Otago, Dunedin, New Zealand, 6Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 7University of Otago, Christchurch, New Zealand

    Background/Purpose: Allopurinol is the most widely used urate-lowering drug. However, some patients treated with allopurinol do not achieve serum urate (SU) treatment target of <6mg/dl,…
  • Abstract Number: 1111 • 2017 ACR/ARHP Annual Meeting

    Protective Effect of Allopurinol Use on Kidney Function Among Patients with Gout and Chronic Kidney Disease

    Ana Beatriz Vargas-Santos1, Christine Peloquin2, Yuqing Zhang3,4 and Tuhina Neogi4, 1Internal Medicine - Rheumatology, State University of Rio de Janeiro, Rio de Janeiro, Brazil, 2Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 3School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: There is increasing evidence that allopurinol may be protective of kidney function among hyperuricemic subjects, though clinicians are often cautious about using allopurinol in…
  • Abstract Number: 1113 • 2017 ACR/ARHP Annual Meeting

    Risk of Cardiovascular Events in Older Patients with Gout Initiating Probenecid Versus Allopurinol: A Population-Based Cohort Study

    Seoyoung C. Kim1, Tuhina Neogi2, Eun Ha Kang3, Jun Liu4, Rishi J. Desai5, MaryAnn Zhang6 and Daniel H. Solomon7, 1Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 2Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 3Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), 4Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 5Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 6Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Gout is associated with an increased risk of cardiovascular (CV) disease including myocardial infarction (MI), stroke and heart failure (HF). Although both probenecid and…
  • Abstract Number: 1118 • 2017 ACR/ARHP Annual Meeting

    Diabetes and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization

    Douglas C.A. Taylor1, An-Chen Fu1 and Robert Morlock2, 1Ironwood Pharmaceuticals, Inc., Cambridge, MA, 2YourCareChoice, Ann Arbor, MI

    Background/Purpose: Gout and type 2 diabetes mellitus (T2DM) are common in the United States (US), but little is known about potential associations of T2DM and…
  • Abstract Number: 1120 • 2017 ACR/ARHP Annual Meeting

    Less Than Half of Patients Treated with High-Dose Allopurinol Reach Serum Uric Acid Target

    Robert Morlock1, Douglas C.A. Taylor2 and Scott Baumgartner3, 1YourCareChoice, Ann Arbor, MI, 2Ironwood Pharmaceuticals, Inc., Cambridge, MA, 3drB Consulting, Spokane, WA

    Background/Purpose: Although allopurinol is FDA approved for up to 800 mg per day and EMEA authorized for up to 900 mg per day, most patients…
  • Abstract Number: 1137 • 2017 ACR/ARHP Annual Meeting

    Urate Lowering to ACR-Recommended Targets Allows Significant Improvement of Severe Gout: A Monocentric Prospective Trial in Vietnam, Using a Systematic Treatment Protocol

    Thomas Bardin1,2,3, Quang Nguyen Dinh1, Khoi Tran Minh1, Nghia Le Hieu1, Minh Do Duc4, Pascal Richette5,6 and Matthieu Resche-Rigon3,7, 1French-Vietnamese Gout Research Center, Ho Chi Minh City, Viet Nam, 2Rheumatology, Hôpital Lariboisière, Paris, France, 3Université Paris Diderot, Paris, France, 4Molecular Biology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam, 5Rhumatologie, Hôpital Lariboisière, Paris, France, 6Rheumatology Department, Université Paris Diderot, Paris, France, 7Biostatistics, Hôpital Saint-Louis, Paris, France

    Background/Purpose: Gout is frequent and severe in Vietnam, where urate-lowering drugs (ULD) are seldom used and many patients are treated only with traditional herbal medicine.…
  • Abstract Number: 1144 • 2017 ACR/ARHP Annual Meeting

    Initiating Colchicine and Urate-Lowering Therapy Reduces Baseline Inflammation, and Improves Vascular Endothelial but Not Smooth Muscle Function in Gout Subjects: Resistance to Endothelial Improvement Among Patients with Cardiovascular Comorbidities

    Talia Igel1,2, Aaron Garza Romero2, Virginia Pike3, Yu Guo4, Stuart Katz5, Binita Shah5, Irina Dektiarev5, Svetlana Krasnokutsky Samuels2 and Michael Pillinger2, 1Medicine, Monash University School of Medicine, Melbourne, Australia, 2Medicine/Rheumatology, New York University School of Medicine, New York, NY, 3Medicine/Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, 4Population Health/Statistics, New York University School of Medicine, New York, NY, 5Medicine/Cardiology, New York University School of Medicine, New York, NY

    Background/Purpose: We have previously reported that patients with gout have impaired vascular endothelial and smooth muscle responsiveness, but whether initiating appropriate gout therapy ameliorates these…
  • Abstract Number: 2058 • 2017 ACR/ARHP Annual Meeting

    A Study on Febuxostat Prescribing Practices for Patients with Chronic Gout Previously Managed with Allopurinol at the Veterans Affairs Puget Sound

    Percy Balderia and Elizabeth R. Wahl, Rheumatology, University of Washington School of Medicine, Seattle, WA

    Background/Purpose: American College of Rheumatology (ACR) guidelines recommend use of either allopurinol or febuxostat as first-line approaches to urate lowering therapy in gout. Prior studies…
  • Abstract Number: 2059 • 2017 ACR/ARHP Annual Meeting

    Allopurinol Dose-Titration Patterns Relative to Serum Uric Acid Levels in Gout Patients: US Electronic Health Record Data

    An-Chen Fu, Douglas C.A. Taylor and David S. Reasner, Ironwood Pharmaceuticals, Inc., Cambridge, MA

    Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Allopurinol is a first-line urate-lowering therapy…
  • Abstract Number: 2265 • 2017 ACR/ARHP Annual Meeting

    Survey on Gout-Related Knowledge and Perception in Inpatient Setting on Hospitalized Patients with Gout

    Roshanak Habibi1, David T Liss2, Sreelakshmi Panginikkod1, Alvaro Altamirano Ufion3, Ehsan Rajabirostami1 and Manish Jain4, 1Internal Medicine, Presence Saint Francis Hospital, Evanston, IL, 2Northwestern University, Chicago, IL, 3Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, 4Rheumatology, Presence Saint Francis Hospital, Evanston, IL

    Background/Purpose: The increasing global burden of gout disease and its impact on the patient’s quality of life calls for new strategies in management. Even though…
  • Abstract Number: 2844 • 2017 ACR/ARHP Annual Meeting

    Risk of Cardiovascular Events in Older Patients with Gout Initiating Febuxostat Versus Allopurinol: A Population-Based Cohort Study

    MaryAnn Zhang1, Jun Liu2, Eun Ha Kang3, Rishi J. Desai4, Tuhina Neogi5, Daniel H. Solomon1 and Seoyoung C. Kim1, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 3Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), 4Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 5Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: Gout, a disorder of uric acid deposition, is commonly treated with xanthine oxidase inhibitors like febuxostat and allopurinol.  While it is well-known that patients…
  • Abstract Number: 2848 • 2017 ACR/ARHP Annual Meeting

    Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-Up) Study

    Ted R. Mikuls1, TC Cheetham2, Gerald D. Levy3, Nazia Rashid4, Kimberly Low5, Brian W Coburn6, Kenneth Saag7, Lang Chen8 and Jeffrey R. Curtis9, 1Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, 3Internal Medicine/Rheumatology, Kaiser Permanente Southern California, Downey, CA, 4Pharmacy Analytic Services, Kaiser Permanente Southern California, Downey, CA, 5Kaiser Permanente Southern California, Panorama City, CA, 6Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 7Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 8University of Alabama at Birmingham, Birmingham, AL, 9Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose:   Allopurinol is a cornerstone therapy in gout management.  Despite this, allopurinol use is suboptimal as providers often fail to follow the treat-to-target paradigm…
  • Abstract Number: 194 • 2016 ACR/ARHP Annual Meeting

    Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout

    Jesse Hall1, Michael Gillen2, Xiaojuan Yang1, Sha Liu1, Susan Walker1, Vicki Clauson1 and Martin Kankam3, 1Ardea Biosciences, Inc., San Diego, CA, 2AstraZeneca, Gaithersburg, MD, 3Vince and Associates Clinical Research, Inc.,, Overland Park, KS

    Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of hyperuricemia and gout. This Phase 1, single-blind,…
  • Abstract Number: 196 • 2016 ACR/ARHP Annual Meeting

    Pharmacodynamic Effects and Safety of Verinurad in Combination with Allopurinol Versus Allopurinol Alone in Adults with Gout: A Phase 2a, Open-Label Study

    Roy Fleischmann1, Peter Winkle2, Jesse Hall3, Xiaohong Yan3, Jeffrey N. Miner3,4, Liz Hicks3, Shakti Valdez3 and Martha Hernandez-Illas5, 1Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 2Anaheim Clinical Trials, Anaheim, CT, 3Ardea Biosciences, Inc., San Diego, CA, 4Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, 5QPS MRA (Miami Clinical Research), Miami, FL

    Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…
  • Abstract Number: 201 • 2016 ACR/ARHP Annual Meeting

    Allopurinol Reduces the Risk of Myocardial Infarction (MI) in the Elderly: A Study of Medicare Claims

    Jasvinder A. Singh1 and Shaohua Yu2, 1Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: To assess whether allopurinol use reduces the risk of myocardial infarction (MI) in the elderly. Methods: We used the 2006-2012 5% random sample of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology